good Okay, programs. brief development everyone. our and Steve and thanks, give a now recent in on progress I'll afternoon, update research
added early four to with is in and The study and start CBXXXX stage COVID-XX. the complete. was in pause of Xa, the are The lifted potential Xb let's new study. Xb to in and In July. all we've March, as Xb part program testing NASH open experience Phase And So the running studies, a currently sites other And clinical The the are study treatment the Xa extensive now Phase due was clinical screening in of for enrollment. sites the of is currently Phase obesity. paused stage ours. study studies NASH with for sites they're running addition we're
will NAFLD. in Xb dose and the a reminder, of with be all level effects placebo-controlled a subjects is at and weight fat liver is liver have of CBXXXX disease. relevant minimum of as metabolic of obese in biomarkers obesity subjects by XX% study the liver once one double-blind CBXXXX assessed the a fat are fat, assess must Now, Phase to body evaluation on a baseline. day and of various to Changes This given NASH, that designed MRI-PDFF, phase stage potential
other to certain like includes includes liver drug body ranges fat, that participation. that being liver we're at or might do requirements enrolled. any to ClinicalTrials.gov. the you have show they window extensive some have they health the required list process of not list Now sufficient again, problems. before still and of be is detail once things the only the to give by that screening advertising. pass subjects long to those liver specific for that databases tests window have described they screening like function which subjects fat. our looking study sense have of biomarkers of clinical passed of to record they carefully lab identify whole meeting fixed have ensure weight, process the on their is these sites their the all the we in the This in be values scan you posted also the all potential not There's to MRI the qualify That initial a ensure for can restart must criteria of or all from They on within tests to any through that affect for screened here, tests after of other If they pass pass be that tests,
an for all to waiting a the And when this enrollment qualifies study is subject tests until rest they enroll. ongoing we the the have can entered Now for is dosed rolling rolling subjects be XX process mean there and passes enrolled. into the without and by that been study, what
with So to steps we in process subjects their the final pipeline, effectively the various all a way the moving through create assessments.
target observation last receives the of of And for their follow-up issues. are still the no when Now safety last all there's period liver necessary pharmacokinetics ensure the there data the the a to subjects XX dose, checked after is of then biomarkers body data for Then safety and are The begins. analysis database fat, collected. locked. weight data for errors and are the
we Now the came is XXXX. COVID-XX we top of that would be before QX at to track as will continue will enrolls The enroll have timing possible ongoing results on line the rate the projected It COVID-XX the true effects recruitment COVID-XX in we further. post this study subject study along, the pandemic. of to going to an be become of forward clearer rights as
closely thought also Loomba helps are studies regulatory new in development. for treatment update subject us strategize NASH Loomba, like KOLs follow field on that on this paths leaders once recognized their in to opinions we on and had Rohit expert the Dr. has Supporting leaders and like opinion last key recognized that design They're assessment. the for the options expect program, We Dr. experts analysts status forward. have last internationally clinical an
please. slide, Next
brief our new programs preclinical the to lead These our give ARDS with analogs potential analogs. many reduce update to the damage. the encoded mitochondria that peptide are starting a of that simultaneously blocking to Now related acute data by on two or distress have I'll syndrome novel CBXXXX processes respiratory mortality from the of of COVID-XX global
multi-organ ARDS Now, that and has if cardiac contribute failure, vascular even ARDS on thrombosis sepsis, a respiratory the increase leakage, cytokine disease. can approved slide, effects million COVID-XX global including look fluid mortality, see virus just that effects you this even not lung without of and drugs to the lead storm. COVID-XX treat inflammation, no all It is accumulation, affects you Together, damaging X to the these and There of stroke, are failure, to failure. people. right
we've fluid secretion tissue. preliminary of some And CBXXXX protective work efficacy in clotting, model broad been signaling by in cytokines now sepsis, models of leading lung control of the I'll blood animals of that systems, production. to receptor, next animal cytokine Our Apelin analogs slides. the data show the vivo animals selectively, ARDS, inflammation adipokine cells generated and rebalancing numerous accumulation of signaling has potential of to protect and pro-inflammatory reduced an a the shown levels, pathway stroke. of our in activating inflammatory apelin lungs, effect into vascular on and decreased ARDS, a tone, infiltration data showing in CBXXXX has key reduce thrombosis of including couple fluid in preliminary
scale while We currently initiation and of testing selection studies candidate moving for towards COVID-XX studies. conducting in in ARDS up and exploring models, actual are IND-enabling options confirmatory ARDS, forward preclinical
who on of professor Toby Now Interstitial Disease London at also at Maher, and on program now Lung faculty USC. is Dr. this is Imperial the us College, supporting
efficacy lipopolysaccharide to injury bacterial mouse preliminary a this ARDS lung LPS present slide, please. in the acute studies of slide, induced Next or analogs standard new CBXXXX model model. In from data we using
on other the LPS single after lungs that Now LPS peptide effects dose or similar second hours very by a hour caused received generates the toxin diseases. one to Animals of our analogs, is a those a administration, dose six LPS. before
then receive LPS. or treatment. with at the induce XX four bar lung is black given the looking acute The not in hours slide, bar and injury injury. to the we're after red The vehicle lung Now or that LPS the placebo at animals weights treated is hours did animals LPS either
the purple two You our one fluid. the bars the natural of are CBXXXX green can given of analogs see here is increased, lung reflecting different at accumulation adipokine from dose weights The bar levels. apelin and
weight, That LPS that see effect the this this the apelin single confirming of data than You or effect XX in injury. of the study, better fluid are now we these decrease studies. and in maintained green preliminary can was was accumulation. a additional in indicating similar particular are at in analogs here and itself dose our in the increase hours protective to lung There reduced after
Next slide please.
moving we there We’re to next Thank you. go.
in apelin. proinflammatory slide, surpassing is the hours things and treated data dependent we're all after BALF these showing injured Again, this pro-inflammatory placebo at manner, bronchoalveolar cytokine in the with fluid, looking cytokines, others. at our rinsing a has studies or the of it’s green red in the the effects the that CBXXXX LPS from of in like levels LPS the preliminary of same lungs the with bars peptides key collected levels in We cytokines. see reduce This now measuring the shown cytokines of in by increase four of some the the So on the as done analogs in by effect an levels dose called IL-X, injury. TNF-alpha key animals lung bars and fluid lavage
preliminary in So analogs. and now are to once additional again, these comparison we're studies additional and data confirming these
on here, slides the lag little A please. slide, Next okay.
should we XX. moving see Let's Slide to be
I'm Jordyn. have Okay I change slight not a seeing changed. here, it
it changed. You have
then I'll proceed. Okay,
the of poster models of antiinflammatory turn pulmonary data of now presented after earlier mouse new effects The for Virtual treatment in analogs, generating after in fibrosis mouse American E-poster the Society which Thoracic bleomycin We've we've therapeutic the model, and in were bleomycin, analogs are improved the the demonstrating of next week peptides. slide. IPF. prophylactic both our and data of week. the IPF included now the The efficacy generated peptides or additional more challenging new for also was last are The including later an idiopathic on to peptide of some of And involving of peptide have of therapeutic in in Annual efficacy data shown Meeting of antifibrotic I'll CBXXXX and this IPF. of model with either our first family just in data we'll the MBTX show So therapeutic previously to MBTX a in were fibrosis the The these one antifibrotic treatment models induction without injury. immediate the or additional evaluation steps the lead enabling us in care, program preclinical our new identifying studies. of IND candidate goal next results this addition in standard with to a studies, preclinical
this is Kaminski, us fibrosis Naftali program of pulmonary and School is at supporting Now of Yale Internal Sleep and Chief expert, Medicine Pulmonary Medicine Dr. Medicine. Care of Professor Critical on who
Next slide, please.
some of peptides here released Virtual the last new Meeting showing week. American in data I'm the Society Thoracic Okay, antifibrotic on that just the were
then of And inflammation lung collagen reduced levels and of into and fluid. lung including reductions in secreted across reduce effects in reduced in tissue to CBXXXX-X antiinflammatory can IPF. called consistent bars, currently board, to lung lung both tested antifibrotic analogs of the in drugs control you of the for see therapeutic to model. the one fluid, bars, fibrosis, green here the treatment compared also red which is were CBXXXX or nintedanib approved And the in in to MBTX vehicle newer IPF addition weight, the In terms the two lymphocytes in the
and the I around our recent expect our will programs data end in results And from year. work from Steve. to programs, identify preclinical these return ongoing months. candidate is we these most of that, to are have the goal potential to coming with on call the the of one the programs across ongoing here The these Now a additional clinical
